Study of the influence of methotrexate on bone metabolism

Authors

  • V.I. Bumeister Sumy State University, Sumy, Ukraine
  • V.Z. Sikora Sumy State University, Sumy, Ukraine
  • T.V. Riabenko Sumy State University, Sumy, Ukraine
  • O.S. Yarmolenko Sumy State University, Sumy, Ukraine
  • S.M. Dmytruk Sumy State University, Sumy, Ukraine
  • L.I. Kiptenko Sumy State University, Sumy, Ukraine
  • A.O. Ponyrko Sumy State University, Sumy, Ukraine
  • T.P. Teslyk Sumy State University, Sumy, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2024.3.7-12

Keywords:

methotrexate, physiological and reparative bone regeneration, oncology, rheumatoid arthritis.

Abstract

Actuality. The review highlights the peculiarities of the effect of methotrexate on the processes of physiological and reparative regeneration of bone tissue. Methotrexate is widely prescribed for the treatment of a large number of diseases, the course of which can be complicated by the occurrence of fractures. A feature of the use of the drug is a long period of prescription. Objective.To investigate the effect of methotrexate on the processes of physiological and reparative regeneration of bone tissue. Methods. A wide analysis of modern literary scientific data on the effect of methotrexate on the processes of physiological and reparative regeneration of bone tissue in scientific and metric databases PubMed, Web of Science, Google Scholar was carried out. Results. Treatment with methotrexate has a negative effect on the processes of physiological regeneration, which is manifested by the delayed formation of trabecular bone, increased resorption of bone tissue, the development of obesity in the bone marrow, and has an inhibitory effect on reparative regeneration, which is manifested by a delay in the formation of bone regenerate in the fracture area, a decrease in the mineralization of injured long tubular bones of the skeleton. Conclusion. Methotrexate slows down the processes of physiological and reparative regeneration, which with long-term use leads to the development of osteoporosis and delayed healing of bone fractures.

References

  1. Valerio V, Kwok M, Loewen H, Winkler J, Mody GM, Scuccimarri R, Colmegna I. Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. Clinical Rheumatology. 2021;40:1259-1271. DOI:10.1007/s10067-020-05363-2
  2. Wang H, Zheng H, Ma Y. Drug treatment of ankylosing spondylitis and related complications: an overlook review. Annals of Palliative Medicine. 2020;9(4):2279285-2272285. DOI: 10.21037/apm-20-277
  3. Athanassiou P, Athanassiou L. Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus. Life. 2023;13(7):1496. DOI:10.3390/life13071496
  4. Van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NS, Tielemans M. Therapeutic drug monitoring of methotrexate in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. 2023;58(11-12):1151-1162. DOI:10.1111/apt.17719
  5. Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflammatory bowel diseases. 2016;22(1):224-233. DOI:10.1097/MIB.0000000000000589
  6. Baggio S, Garzon S, Russo A, et al. Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management. Arch Gynecol Obstet. 2021;303:259–268. DOI:10.1007/s00404-020-05749-2
  7. Shouman MT, Mansour OM, El Gammal MM, Abdel-Fattah RM, Samra MA, Elhaddad AM, Mahmoud HK. Post-transplantation cyclophosphamide-based graft-versus-host-disease prophylaxis compared to methotrexate-cyclosporine a in matched-related allogeneic hematopoietic stem cell transplantation. Hematology/Oncology and Stem Cell Therapy. 2023;16(4):379-387. DOI: 10.56875/2589-0646.1065
  8. Mansour A, Mahmoud MY, Bakr AF, Ghoniem MG, Adam FA, El-Sherbiny IM. Dual-enhanced pluronic nanoformulated methotrexate-based treatment approach for breast cancer: Development and evaluation of in vitro and in vivo efficiency. Pharmaceutics. 2022;14(12):2668. DOI:10.3390/pharmaceutics14122668
  9. Levêque D, Becker G, Toussaint E, Fornecker LM, Paillard C. Clinical pharmacokinetics of methotrexate in oncology. International journal of Pharmacokinetics. 2017;2(2):137-147. DOI:10.4155/ipk-2016-0022
  10. Villanueva G, Guscott M, Schaiquevich P, Sampor C, Combs R, Tentoni N, Howard S. A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma. Cancers. 2023;15(5):1459. DOI:10.3390/cancers15051459
  11. Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, Cvejic J, Mooranian A, Al-Salami H, Golocorbin-Kon S. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Molecular biology reports. 2020;47:4699-4708. DOI:10.1007/s11033-020-05481-9
  12. Hryvkova LV. [High-dose methotrexate-containing antitumor chemotherapy]. Practical oncology. 2021;4(1):30–38. Ukrainian. DOI:10.22141/2663-3272.4.1.2021.229869
  13. Strazzulla LC, Cronstein BN. Regulation of bone and cartilage by adenosine signaling. Purinergic Signalling. 2016;12:583–593. DOI:10.1007/s11302-016-9527-2
  14. Leonardo N, Lester S, Graham M, Barrett C, Whittle S, Rowett D, Hill CL. Selection and perception of methotrexate treatment information in people with rheumatoid arthritis. International Journal of Rheumatic Diseases. 2020;23(6):805-812. DOI: 10.1111/1756-185X.13833
  15. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, Gasque P. Methotrexate an old drug with new tricks. International journal of molecular sciences. 2019;20(20):5023. DOI:10.3390/ijms20205023
  16. Zhang Y, Sun L, Chen X, Zhao L, Wang X, Zhao Z, Mei S. A systematic review of population pharmacokinetic models of methotrexate. European Journal of Drug Metabolism and Pharmacokinetics. 2022;47(2):143-164. DOI:10.1007/s13318-021-00737-6
  17. Campbell JM, Bateman E, Stephenson MD, Bowen JM, Keefe DM, Peters MDJ. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemotherapy and Pharmacology. 2016;78(1):27–39.
  18. Dalix E, Maalouf M, Peyroche S, Vanden-Bossche A, Arthaud CA, Hodin S, Marotte H. Similar effect of co-administration of methotrexate and folic acid for the treatment of arthritis compared to separate administration. Rheumatology. 2023;62(4):1706-1710. DOI:10.1093/rheumatology/keac579
  19. Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, Rahaf H. Overview of Methotrexate Toxicity: A Comprehensive Literature Review. 2022;14(9):29518. DOI 10.7759/cureus.29518
  20. Robin F, Cadiou S, Albert JD, Bart G, Coiffier G, Guggenbuhl P. Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int. 2021;32:225–232. DOI:10.1007/s00198-020- 05664-x
  21. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. European journal of medicinal chemistry. 2018;158:502-516. DOI:10.1016/j.ejmech.2018.09.027
  22. Ryan C, Stoltzfus KC, Horn S, Chen H, Louie AV, Lehrer EJ, Zaorsky NG. Epidemiology of bone metastases. Bone. 2022;158:115783. DOI:10.1016/j.bone.2020.115783
  23. Marongiu G, Dolci A, Verona M, Capone A. The biology and treatment of acute long-bones diaphyseal fractures: Overview of the current options for bone healing enhancement. Bone reports. 2020;12:100249. DOI:10.1016/j.bonr.2020.100249
  24. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. The oncologist. 2016;21(12):1471-1482. DOI:10.1634/theoncologist.2015-0164
  25. Yang V, Gouveia MJ, Santos J, Koksch B, Amorim I, Gärtner F, Vale N. Breast cancer: insights in disease and influence of drug methotrexate. RSC Medicinal Chemistry. 2020;11(6):646-664.
  26. Daetwyler E, Bargetzi M, Otth M, et al. Late effects of high-dose methotrexate treatment in childhood cancer survivors—a systematic review. BMC Cancer. 2022;22:267. DOI:10.1186/s12885-021-09145-0
  27. Georgiou KR, Nadhanan RR, Fan CM, Xian CJ. Methotrexate-induced bone marrow adiposity is mitigated by folinic acid supplementation through the regulation of Wnt/β-catenin signalling. Journal of Cellular Physiology. 2015;230(3):648-656. DOI:10.1002/jcp.24788
  28. Peymanfar Y, Su Y-W, Hassanshahi M, Xian CJ. Therapeutic Targeting Notch2 Protects Bone Micro-Vasculatures from Methotrexate Chemotherapy-Induced Adverse Effects in Rats. Cells. 2022;11(15):2382. DOI:10.3390/cells11152382
  29. Su YW, Lee AM, Xu X, Hua B, Tapp H, Wen XS, Xian CJ. Methotrexate Chemotherapy Causes Growth Impairments, Vitamin D Deficiency, Bone Loss, and Altered Intestinal Metabolism—Effects of Calcitriol Supplementation. Cancers. 2023;15(17):4367. DOI:10.3390/cancers15174367
  30. Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M, Liu Y. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomedicine Pharmacotherapy. 2022;150:113074. DOI: 10.1016/j.biopha.2022.113074
  31. Fan C, Georgiou KR, King TJ, Xian CJ. Methotrexate toxicity in growing long bones of young rats: a model for studying cancer chemotherapy-induced bone growth defects in children. Journal of Biomedicine and Biotechnology. 2011. Article ID 903097, 8 p. https://doi.org/10.1155/2011/903097
  32. Kanagawa H, Masuyama R, Morita M, Sato Y, Niki Y, Kobayashi T, Miyamoto T. Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors. J Bone Miner Metab. 2016;34:526–531. DOI:10.1007/s00774-015-0702-2
  33. Pountos I, Giannoudis PV. Effect of methotrexate on bone and wound healing. Expert Opinion on Drug Safety. 2017;16(5):535-545. DOI:10.1080/14740338.2017.1310839
  34. Zhang Y, Liu L, Pillman KA, Hayball J, Su Y-W, Xian CJ. Differentially expressed miRNAs in bone after methotrexate treatment. Journal of Cellular Physiology. 2022;237(1):965-982. DOI: 10.1002/jcp.30583
  35. Lee AM, Shandala T, Soo PP, Su YW, King TJ, Chen KM, Xian CJ. Effects of resveratrol supplementation on methotrexate chemotherapy-induced bone loss. Nutrients. 2017;9(3):255. DOI: 10.3390/nu9030255
  36. Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, Ridker PM. Adverse effects of low-dose methotrexate: a randomized trial. Annals of internal medicine. 2020;172(6):369-380. DOI: 10.7326/M19-3369
  37. El Miedany Y. FRAX: re-adjust or re-think. Arch Osteoporos. 2020;15:1-8. DOI: 10.1007/s11657-020-00827-z
  38. Abolmaali SS, Tamaddon AM, Dinarvand RA. Review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer chemotherapy and pharmacology. Cancer Chemother Pharmacol. 2013;71:1115–1130. DOI:10.1007/s00280-012-2062-0
  39. Robin F, Cadiou S, Albert JD, Bart G, Coiffier G, Guggenbuhl P. Methotrexate osteopathy: five cases and systematic literature review. Osteoporosis International. 2020:1-8. DOI:10.1007/s00198-020-05664-x
  40. Tresguerres FGF, Torres J, López-Quiles J, Hernández G, Vega JA, Tresguerres IF. The osteocyte: a multifunctional cell within the bone. Ann Anat Anat Anz. 2020;227:151422. DOI: 10.1016/j.aanat.2019.151422
  41. Olsen NJ, Spurlock CF, Aune TM. Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis research & therapy. 2014;16(1):1-8. DOI:10.1186/ar4444
  42. Świerkot J, Gruszecka K, Matuszewska A, Wiland P. Assessment of the effect of methotrexate therapy on bone metabolism in patients with rheumatoid arthritis. Archivum Immunologiae et Therapiae Experimentalis. 2015;63:397-404. DOI: 10.1007/s00005-015-0338-x

Downloads

Published

2024-10-30

How to Cite

Bumeister , V., Sikora , V., Riabenko , T., Yarmolenko , O., Dmytruk , S., Kiptenko , L., Ponyrko , A., & Teslyk , T. (2024). Study of the influence of methotrexate on bone metabolism. Морфологія / Morphologia / Morfologìâ, 18(3), 7–12. https://doi.org/10.26641/1997-9665.2024.3.7-12

Issue

Vol. 18 No. 3 (2024)

Section

Статті

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.